title: Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.
abstract: OBJECTIVE
  To report our experience with both (123)I-vasoactive intestinal peptide (VIP) and (111)In-DTPA-D-Phe(1)-octreotide for imaging to identify primary and metastatic tumor sites in carcinoid patients.
  
  
  METHODS
  One hundred ninety-four patients with a verified or clinically suspected diagnosis of a carcinoid tumor were injected with (111)In-DTPA-D-Phe(1)-OCT for imaging purposes, while 133 patients underwent scanning with both (123)I-VIP and (111)In-DTPA-D-Phe(1)-OCT in random order. Imaging results were compared with computed tomography scans, results of conventional ultrasound, endosonography, and endoscopy, and results of surgical exploration in case of inconclusive conventional imaging.
  
  
  RESULTS
  Primary or recurrent carcinoid tumors could be visualized with (111)In-DTPA-D-Phe(1)-OCT in 95 (91%) of 104 patients; metastatic sites were identified in 110 (95%) of 116 patients. In 11 (51%) of 21 patients with suggestive symptoms but without identified lesions by conventional imaging, focal tracer uptake located the carcinoid tumor. In addition, metastatic disease was demonstrated in three patients after resection. In a direct comparison in the 133 patients who underwent both imaging modalities, (111)In-DTPA-D-Phe(1)-OCT was found to be superior to (123)I-VIP, with 35 (93%) of 38 versus 32 (82%) of 38 scans being positive in primary or recurrent tumors, 58 (90%) of 65 versus 53 (82%) of 65 being positive in patients with metastatic sites, and seven (44%) of 16 versus four (25%) of 16 being positive in patients with symptoms but otherwise negative work-ups. Overall, additional lesions not seen on conventional imaging were imaged in 43 (41%) of 158 versus 25 (25%) of 103 scans with (111)In-DTPA-D-Phe(1)-OCT and (123)I-VIP, respectively.
  
  
  CONCLUSIONS
  Both peptide tracers have a high sensitivity for localizing tumor sites in patients with ascertained or suspected carcinoid tumors, with (111)In-DTPA-D-Phe(1)-OCT scintigraphy being more sensitive than (123)I-VIP receptor scanning. Both, however, had a higher diagnostic yield than conventional imaging, as verified by surgical intervention or long-term follow-up. The combination of both peptide receptor scans does not seem to further enhance diagnostic information.
authors.affiliation: Department of Internal Medicine I, University of Vienna, and Research Center Seibersdorf, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Raderer
authors.forename: A
authors.initials: A
authors.lastname: Kurtaran
authors.forename: M
authors.initials: M
authors.lastname: Leimer
authors.forename: P
authors.initials: P
authors.lastname: Angelberger
authors.forename: B
authors.initials: B
authors.lastname: Niederle
authors.forename: H
authors.initials: H
authors.lastname: Vierhapper
authors.forename: F
authors.initials: F
authors.lastname: Vorbeck
authors.forename: M H
authors.initials: MH
authors.lastname: Hejna
authors.forename: W
authors.initials: W
authors.lastname: Scheithauer
authors.forename: J
authors.initials: J
authors.lastname: Pidlich
authors.forename: I
authors.initials: I
authors.lastname: Virgolini
mesh_terms: D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging*; D006801:Humans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives*; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon; D014660:Vasoactive Intestinal Peptide
chemical_list: D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C406248:iodinated vasoactive intestinal peptide; C071632:SDZ 215-811; D014660:Vasoactive Intestinal Peptide; D004369:Pentetic Acid; D015282:Octreotide